First-Third generation EGFR inhibitor combined with cytotoxic
chemotherapy in elderly Patients with advanced lung adenocarcinom in
routine clinical practice-results from A Subgroup Analysis
Abstract
Abstract In this study,we investigated a the combination of osimertinib/
gefitinib/ erlotinib with cytotoxic chemotherapy for EGFR-mutated
positive lung adenocarcinoma patients in long-term survival outcomes.
Method We enrolled Ⅲb-IV stage lung adenocarcinoma patients,Patients
receiving standard Osimertinib,Gefitinib,Erlotinip alone treatment and
Osimertinib,Gefitinib and Erlotinip with cytotoxic chemotherapy were
retrospectively reviewed. Result First generation Chemical-TKItherapy
PFS vs First generation TKI therapy alone PFS.P<0.05.Mean
Survival Time(MST)22.00 month VS 16.00.OS P<0.05. MST 32.00
month VS 28.00.Third generation Chemical-TKItherapy PFS vs Third
generation TKI therapy alone PFS.P<0.001.MST 40.00 month VS
26.66. OS P<0.05.MST 48.00 month VS 36.00.First-Third
generation Chemical-TKItherapy PFS vs First-Third generation TKI therapy
alone PFS.P<0.001.(MST)28.00 monthVS 17.00.OS
P<0.001.MST 41,00 month.VS 29.00.Cox regression models showed
a significant prognostic factors for OS were old age (55-69 years)
(HR 0.49 [0.28–0.89], p < 0.02) and gene mutation
(Positive) (HR 0.15 [0.07–0.29], p < 0.05),First add
third generationTKI with chemicaltherapy (HR 0.56 [0.35–0.89],
p < 0.02). Conclusion The results obtained under real-life
conditions add to our understanding of the benefits and risks of
First-Third generation EGFR inhibitor combined with cytotoxic
chemotherapy in routine clinical practice.